Kiniksa Pharmaceuticals International Plc(KNSA) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Oct 28 at 7:18 PM ET (Korea 10/29 08:18)
Full metrics table
| Index | RUT | P/E | 72.62 | EPS (ttm) | 1.31 | Insider Own | 42.3% | Shs Outstand | 48.8M | Perf Week | 19.42% |
| Market Cap | 7.43B | Forward P/E | 46.82 | EPS next Y | 39.98% | Insider Trans | -1.89% | Shs Float | 45.0M | Perf Month | 25.68% |
| Enterprise Value | 6.87B | PEG | 0.84 | EPS next Q | 0.25 | Inst Own | 60.44% | Short Float | 8.36% | Perf Quarter | 21.71% |
| Income | 0.11B | P/S | 7.85 | EPS this Y | 93.63% | Inst Trans | 2.03% | Short Ratio | 5.85 | Perf Half Y | 79.62% |
| Sales | 0.95B | P/B | 10.52 | EPS next 5Y | 55.9% | ROA | 12.92% | Short Interest | 3.76M | Perf YTD | 130.74% |
| Book/sh | 9.05 | P/C | 13.06 | EPS past 3/5Y | -34.04% - | ROE | 17.59% | 52W High | 4.82% ($90.80) | Perf Year | 141.39% |
| Cash/sh | 7.29 | P/FCF | 37.66 | Sales past 3/5Y | 45.45% - | ROIC | 15.34% | 52W Low | 170.4% ($35.20) | Perf 3Y | 524.13% |
| Dividend Est. | - | EV/EBITDA | 51.87 | EPS Y/Y TTM | 192.34% | Gross Margin | 54.21% | Volatility(W/M) | 7.18% 4.63% | Perf 5Y | 770.02% |
| Dividend TTM | - | EV/Sales | 7.26 | Sales Y/Y TTM | 58.19% | Oper. Margin | 13.79% | ATR (14) | 4.56 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.35 | EPS Q/Q | 142.08% | Profit Margin | 11.58% | RSI (14) | 70.17 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.91 | Sales Q/Q | 58.12% | SMA20 | 19.48% ($79.66) | Beta | 0.1 | Target Price | $106.5 |
| Payout | - | Debt/Eq | 0.01 | Earnings | 2026/10/27 | SMA50 | 21.18% ($78.54) | Rel Volume | 2.65 | Prev Close | $89.2 |
| Employees | 366 | LT Debt/Eq | 0.01 | EPS/Sales Surpr. | 50.94% 9.71% | SMA200 | 59.57% ($59.65) | Avg Volume(3M) | 0.64M | Price | $95.18 |
| IPO | 2018/5/24 | Option/Short | Yes/Yes | Trades | 18433 | Volume | 1,706,806 | Change | 6.7% |
KNSAKiniksa Pharmaceuticals International Plc | NASD | Drug Manufacturers - Specialty & Generic Deep dive💊 A commercial-stage biopharmaceutical company that sells treatments for rare autoimmune and cardiovascular diseases. It commercializes and sells therapies indicated for conditions including recurrent pericarditis, generating stable, profit-based revenues while pursuing pipeline expansion. A biopharmaceutical company specializing in rare diseases.
Over the past 1 year, on the higher side
0% below its 1-year high.
Traded more than usual. That is 265% of its average volume.
KNSA makes money exceptionally well
Of every $100 in sales, $13.79 is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +93.6% this year.
Tap to view numbers
However, it looks expensive
Counting its debt, for $100 of yearly operating cash you would pay $5,187. Peers typically go for $1,429.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have paid off
Bought 5 years ago, your return today would be +770.0%. The S&P 500 did +69% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 60.4%.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #11 of 83 in the industry
Based on market cap of $7B.
ALKS#10 Alkermes plc $8B PER 117.5 KNSA#11 Kiniksa Pharmaceuticals International Plc $7B PER 72.6 
HIMS#12 Hims & Hers Health Inc $7B PER - 
AMRX#13 Amneal Pharmaceuticals Inc $7B PER 44.1 
LNTH#14 Lantheus Holdings Inc $7B PER 24.2 
FAQ
What kind of company is KNSA?
KNSA belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of KNSA?
The market cap of KNSA is approximately $7.4B, ranking 1,094 within its sector.
What is the P/E ratio of KNSA?
KNSA has a P/E ratio of approximately 72.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for KNSA?
KNSA has recorded a 52-week high of $90.80 and a low of $35.20.
